Deakin University
Browse

CDKL3 promotes osteosarcoma progression by activating Akt/PKB

Download (3.7 MB)
Version 2 2024-06-18, 20:16
Version 1 2020-04-08, 15:08
journal contribution
posted on 2024-06-18, 20:16 authored by A He, L Ma, Y Huang, H Zhang, Wei DuanWei Duan, Z Li, T Fei, J Yuan, H Wu, L Liu, Y Bai, W Dai, Y Wang, H Li, Y Sun, C Wang, T Yuan, Q Yang, S Tian, M Dong, R Sheng, D Xiang
Osteosarcoma (OS) is a primary malignant bone neoplasm with high frequencies of tumor metastasis and recurrence. Although the Akt/PKB signaling pathway is known to play key roles in tumorigenesis, the roles of cyclin-dependent kinase–like 3 (CDKL3) in OS progression remain largely elusive. We have demonstrated the high expression levels of CDKL3 in OS human specimens and comprehensively investigated the role of CDKL3 in promoting OS progression both in vitro and in vivo. We found that CDKL3 regulates Akt activation and its downstream effects, including cell growth and autophagy. The up-regulation of CDKL3 in OS specimens appeared to be associated with Akt activation and shorter overall patient survival (P = 0.003). Our findings identify CDKL3 as a critical regulator that stimulates OS progression by enhancing Akt activation. CDKL3 represents both a biomarker for OS prognosis, and a potential therapeutic target in precision medicine by targeting CDKL3 to treat Akt hyper-activated OS.

History

Journal

Life Science Alliance

Volume

3

Article number

ARTN e202000648

Pagination

1 - 16

Location

United States

Open access

  • Yes

ISSN

2575-1077

eISSN

2575-1077

Language

English

Publication classification

C1 Refereed article in a scholarly journal

Issue

5

Publisher

LIFE SCIENCE ALLIANCE LLC

Usage metrics

    Research Publications

    Categories

    No categories selected

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC